EverSource Wealth Advisors’s Standard BioTools LAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$24.3K Buy
26,466
+1,388
+6% +$1.68K ﹤0.01% 2380
2025
Q4
$32.1K Sell
25,078
-113
-0.4% -$152 ﹤0.01% 2053
2025
Q3
$32.7K Buy
25,191
+35
+0.1% +$46 ﹤0.01% 2002
2025
Q2
$30.2K Sell
25,156
-192
-0.8% -$213 ﹤0.01% 1974
2025
Q1
$27.4K Buy
25,348
+1,537
+6% +$2.16K ﹤0.01% 1524
2024
Q4
$41.7K Buy
23,811
+11
+0% +$20 ﹤0.01% 1270
2024
Q3
$45.9K Hold
23,800
﹤0.01% 1107
2024
Q2
$53.3K Hold
23,800
﹤0.01% 1058
2024
Q1
$59K Sell
23,800
-4,000
-14% -$9.66K ﹤0.01% 909
2023
Q4
$61.4K Hold
27,800
0.01% 818
2023
Q3
$80.6K Hold
27,800
0.01% 645
2023
Q2
$53.7K Buy
+27,800
New +$54.9K 0.01% 810
2022
Q2
Sell
-917
Closed -$3K 1807
2022
Q1
$3K Buy
+917
New +$3.17K ﹤0.01% 1423

Other funds holding LAB

EverSource Wealth Advisors's LAB Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Standard BioTools (LAB) stake by 5.5% in Q1 2026, buying an estimated $1.68K and bringing the position to 26,466 shares worth $24.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2380.

EverSource Wealth Advisors first reported a position in LAB in Q1 2022 and has held it in 13 quarters since. The position peaked at $80.6K in Q3 2023. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • EverSource Wealth Advisors held 26,466 shares of Standard BioTools worth $24.3K as of Q1 2026.
  • EverSource Wealth Advisors bought 1,388 Standard BioTools shares in Q1 2026, an estimated $1.68K.
  • Standard BioTools made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #2380 holding.
  • EverSource Wealth Advisors first reported a position in Standard BioTools in Q1 2022 and has held it in 13 quarters since.
  • EverSource Wealth Advisors's Standard BioTools position peaked at $80.6K in Q3 2023.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.